Public Conduct During FDA Advisory Committee Meetings
The FDA would like to ensure that advisory committee meetings proceed in an
orderly fashion, are conducted in a safe and secure environment, that the right
of free speech is protected, and that the ability of FDA Advisory Committees
and Panels to accomplish their objectives is not disrupted. Therefore, the following
procedures will be followed:
- An interested person who wishes to be assured of the right to make an oral
presentation during the Open Public Hearing portion of an advisory committee
meeting should register with FDA before the meeting. See 21 CFR 14.29(b).
Those who have not registered before the meeting will only be invited to speak
at the discretion of the Chair, and should submit their request to FDA officials
at the registration desk on the day of the meeting.
- Open Public Hearing participants who are designated to speak may be questioned
only by the Chair or other members of the Committee.
- Audience members may not present comments or questions to the Committee
unless recognized by the Chair.
- Attendees may be subject to security screening, such as presenting identification,
passing through metal detectors, and inspection of briefcases, packages, etc.
- Attendees at the meeting are asked to maintain order and not display behavior
that is disruptive to the meeting (i.e., shouting from the audience, loud
outbursts).
- The committee Chair or Designated Federal Official will note on the record
any disruptive behavior and will ask the person to cease the behavior or else
leave the meeting room.
- We ask that attendees not approach the advisory committee table area before,
during, or after the meeting without permission from a Designated Federal
Official/Executive Secretary.
